Vesicare
In brief
- In our pharmacy, you can buy Vesicare without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Vesicare (solifenacin succinate) is used to treat overactive bladder symptoms such as urinary urgency, frequency and urge incontinence; it is a muscarinic (antimuscarinic) receptor antagonist that reduces involuntary bladder contractions.
- The usual dose is 5 mg once daily, which may be increased to 10 mg once daily if needed; an oral suspension (1 mg/mL) is also available, typically started at 5 mL (5 mg) once daily and may be increased to 10 mL (10 mg) once daily where appropriate.
- The medicine is taken orally as a film‑coated tablet (5 mg or 10 mg) or as an oral suspension (1 mg/mL).
- Some patients notice symptom improvement within a few days, but meaningful benefit often becomes apparent within about 1 week.
- Vesicare is taken once daily and provides around 24 hours of effect; the drug has a relatively long half‑life so effects accumulate with regular dosing.
- Avoid excessive alcohol while taking Vesicare as alcohol can worsen side effects such as dizziness and may impair bladder control.
- The most common side effect is dry mouth; constipation and blurred vision are also frequently reported.
- Would you like to try Vesicare without a prescription?
Basic Vesicare information
- INN (international nonproprietary name): solifenacin succinate.
- Brand names available in the United Kingdom: Vesicare 5 mg Film-Coated Tablets; Vesicare 10 mg Film-Coated Tablets; Vesicare 1 mg/mL Oral Suspension.
- ATC code: G04BD08.
- Forms and strengths: film-coated tablets 5 mg and 10 mg; oral suspension 1 mg/mL.
- Registration status in the United Kingdom: prescription-only medicine (POM).
- OTC / Rx classification: Rx only.
Legal status and availability in the UK
In our online pharmacy, Vesicare is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Clinical effectiveness in the UK
- Side effects that can affect persistence include dry mouth, constipation and blurred vision.
- Insufficient benefit is a common reason for stopping treatment.
- In specialist urology settings, combining behavioural therapy with solifenacin supports better adherence.
- Clinicians must balance efficacy against cumulative anticholinergic burden, particularly in older adults on other antimuscarinics or tricyclic antidepressants.
Solifenacin is used as a first‑line oral antimuscarinic when behavioural measures such as bladder training are insufficient.
Treatment review at 4–12 weeks aligns with NHS practice to check symptom response and side effects.
Indications and expanded uses
Who is Vesicare licensed for, and when might specialists use it off‑label?
- Licensed uses: Overactive bladder symptoms of urgency, frequency and urge incontinence in adults.
- Specialist paediatric use: Oral suspension 1 mg/mL appears in the UK SmPC for specific settings such as neurogenic detrusor overactivity under specialist supervision.
- Off‑label uses: limited, typically for refractory urgency after conservative measures or as part of specialist combination therapy strategies.
| Population | Typical use |
|---|---|
| Adults | First‑line oral antimuscarinic for OAB after conservative measures; tablets 5 mg/10 mg |
| Children (Specialist Care) | Oral suspension 1 mg/mL for neurogenic detrusor overactivity under specialist supervision |
Initiation commonly occurs in primary care after excluding urinary tract infection and assessing retention risk and comorbidities.
Clinicians should follow MHRA guidance and local formularies when prescribing and consider specialist referral for complex cases.
Composition and brand landscape
What is in the product?
| Formulation | Strength | Notes |
|---|---|---|
| Film‑coated Tablet | 5 mg | Contains solifenacin succinate; 5 mg tablet corresponds to about 3.8 mg solifenacin |
| Film‑coated Tablet | 10 mg | Contains solifenacin succinate; 10 mg tablet corresponds to about 7.5 mg solifenacin |
| Oral Suspension | 1 mg/mL | Listed in the UK SmPC for certain paediatric uses |
Vesicare is the recognised brand name for solifenacin succinate and remains familiar to clinicians and patients in the United Kingdom.
Generic solifenacin tablets are available from multiple manufacturers following patent expiry, and local NHS formularies often list both branded and generic options.
Choice between brand and generic typically reflects local formulary preference.
Contraindications and special precautions — high‑risk groups
Who should not take Vesicare and which patients need extra caution?
- Contraindications: urinary retention, gastric retention, uncontrolled narrow‑angle glaucoma, and known hypersensitivity to solifenacin or excipients.
- Special precautions: older adults because of heightened anticholinergic burden and potential cognitive effects.
- Hepatic and renal considerations: significant hepatic impairment and severe renal impairment need careful assessment and may require dose adjustment or avoidance.
Older adults are at increased risk of anticholinergic cognitive effects and clinicians should routinely assess cumulative anticholinergic burden before starting solifenacin.
Pregnancy and breastfeeding warrant a risk–benefit discussion and solifenacin is usually avoided unless essential.
Driving and operating machinery may be affected if blurred vision or dizziness occur, so patients should be counselled not to drive until they know how the medicine affects them.
Alcohol can worsen central side effects and dry mouth and should be moderated while establishing tolerance.
Report unexpected serious adverse reactions via the MHRA Yellow Card scheme as part of routine vigilance.
Dosage guidelines — NHS recommended regimens and adjustments
How is Vesicare usually started and adjusted in NHS practice?
| Patient group | Typical regimen |
|---|---|
| Adults | Start 5 mg once daily; increase to 10 mg once daily if needed and tolerated |
| Older Adults | Start low (5 mg once daily); consider alternatives if high anticholinergic burden |
| Paediatric NDO (Specialist) | Oral suspension dosing per specialist formularies; suspension concentration 1 mg/mL |
- Titration protocol: start 5 mg once daily, review at 4–12 weeks, consider 10 mg once daily only if benefit is inadequate and adverse effects are acceptable.
- If anticholinergic side effects occur, consider dose reduction or switching to an alternative class such as mirabegron.
Tablets can be taken with or without food at the same time each day to aid adherence.
Treatment review should focus on symptom change, side effects and cumulative anticholinergic load.
Interactions overview
Which medicines and substances interact with solifenacin?
| Interaction partner | Effect and action |
|---|---|
| Other Anticholinergics | Additive anticholinergic effects; avoid combination where possible |
| Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin) | Can increase solifenacin plasma levels; dose adjustment or avoidance may be needed |
| QT‑Prolonging Drugs | Caution advised when combining; monitor and review risks |
| Alcohol | May exacerbate dizziness and dry mouth; advise moderation |
With strong CYP3A4 inhibitors the solifenacin dose should not exceed 5 mg daily. Unexpected serious reactions should be reported via the Yellow Card scheme.
Pharmacists should screen prescriptions for interactions as part of NHS electronic prescribing checks and consider anticholinergic burden calculators for older patients.
Comparable medicines and prescribing preferences — pros and cons
How does solifenacin compare with alternatives such as mirabegron and other antimuscarinics?
- Solifenacin (Vesicare) pros: once‑daily dosing, established efficacy for urgency and incontinence, available as tablets and suspension.
- Solifenacin cons: anticholinergic side effects such as dry mouth and constipation, contributes to cumulative anticholinergic burden.
- Mirabegron pros: avoids anticholinergic burden and may be preferred in older patients or those on multiple antimuscarinics.
- Mirabegron cons: cardiovascular considerations (blood pressure monitoring) may limit use in some patients.
Choice should be guided by patient age, cognitive status, comorbidities, drug interactions and local formulary guidance.
Refer to urology if symptoms are refractory or when combination therapy is being considered.
Frequently asked questions
-
Will Vesicare stop my urinary urgency?
Many patients see a reduction in urgency and incontinence within 2–6 weeks, with follow‑up at 4–12 weeks routine to assess response.
-
What are the main side effects and can I drive?
Common side effects include dry mouth, constipation and blurred vision, and driving may be affected if you feel dizzy or have blurred vision.
-
Can older relatives take Vesicare safely?
Older adults require careful review of cumulative anticholinergic burden and cognition, and mirabegron or lower starting doses are often considered.
-
Is it available without a prescription?
Vesicare is prescription only in the UK and patients should speak to their GP or pharmacist for assessment and a prescription.
Guidelines for proper use
What should pharmacists tell patients when dispensing Vesicare?
- Confirm dosing: 5 mg once daily for adults, increase to 10 mg once daily only if needed and tolerated.
- Explain administration: tablets may be taken with or without food at the same time each day.
- Discuss onset: expect symptom improvement over weeks and review at 4–12 weeks.
- Side‑effect management: suggest sipping fluids for dry mouth and increased fibre for constipation.
- Screening: check for contraindications such as urinary retention, uncontrolled narrow‑angle glaucoma and significant hepatic or renal impairment.
- Interactions: review concomitant anticholinergics and CYP3A4 inhibitors and advise accordingly.
- Driving and alcohol: counsel on avoidance of driving if affected and moderation of alcohol intake while establishing tolerance.
- Follow‑up and reporting: advise review at about 3 months for repeat prescriptions and report suspected adverse effects via the Yellow Card scheme.
Signpost patients to NHS patient portals, local continence services and NHS 111 for additional bladder training resources and support.
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Bristol | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Norwich | England | 9–21 days |
| Plymouth | England | 9–21 days |
| Coventry | England | 9–21 days |
